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Abstract
Background: The HIV/AIDS pandemic has struck regions, countries, and populations in different ways. With the
introduction of antiretroviral drugs, people living with HIV (PLHIV) have a much better prognosis, even though
there are still many new infections in young women. The role of widespread antiretroviral therapy (ART) on the
incidence of HIV in young women is unknown.
Methods: We will conduct a comprehensive search of MEDLINE (PubMed), Excerpta Medica database (EMBASE), Scopus,
Google Scholar, Cochrane Central Register of Controlled Trials (CENTRAL), World Health Organization’s (WHO’s) library
database, Latin American and Caribbean Health Sciences Literature (LILACS), conference abstracts, and gray literature
sources to identify any relevant literature. We will include randomized and non-randomized clinical trials and cohort
studies in which ART was offered to adults aged 18 and above reporting outcomes in females aged 15 to 24 years. The
outcomes of interest are HIV incidence, ART initiation, adherence, retention, and viral load suppression. We will screen
titles, abstracts, and the full texts of relevant articles in duplicate. Disagreements will be resolved by consensus. We will
extract data on the risk of HIV infection in younger females after the use of ART in the adult population.
Discussion: To our knowledge, this is the first systematic review to look at the impact of ART use among adults on HIV
incidence in young women. The results of this review will be used in a modeling study to simulate the effects of using
ART as an effective tool to prevent sexual transmission of HIV to young women. Our findings will inform the treatment-
as-prevention (TasP) strategy to reduce new HIV infections among young women.
Systematic review registration: The systematic review protocol was registered with the International Prospective
Register of Systematic Reviews (PROSPERO), registration number CRD42018099174.
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Background
HIV/AIDS disease burden varies considerably across dif-
ferent regions, countries, and populations. Globally in
2017, there were over 36.9 (95% confidence interval [CI]
31.1–43.9) million people living with HIV of which 19.6
(95% CI 17.5–22.0) million, thus 53% lived in Eastern
and Southern Africa [1]. Although Southern Africa is
home to less than 1% of the global population, the re-
gion has more than a fourth of all HIV infections in the
world [1, 2]. On the other hand, HIV incidence has
halved from 0.1% of the world population in the
mid-1990s to about 0.05% in 2015 [3]. Once thought of
as a death sentence on acquisition, HIV is now viewed
as a chronic, manageable illness due to the advancement
in prevention strategies, education, and research which
saw the introduction of the effective antiretroviral ther-
apy (ART).
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The randomized controlled trials and implementation
studies on HIV treatment which are primarily focused
on adults have reported promising reductions in HIV
transmission in this population group. Most notable is
the HIV Prevention Trials Network 052 (HPTN 052)
trial which reported a 96% decrease in HIV transmission
and 41% decrease in HIV-related morbidity from early
initiation of ART in heterosexual HIV-discordant cou-
ples [4]. On the other hand, the ANRS 12249 trial showed
no decrease in the HIV incidence as a result of universal
test and treat and suggest that if the conditions necessary
(linkage in care, ART coverage, ART adherence, retention
on treatment) are not met, the benefits of universal test
and treat are unlikely to be realized [5]. The ANRS 12249
trial however provided strong evidence on individual
benefits and recommended the roll-out of the universal
test and treat without any restriction. As a result, scale-up
of ART particularly in Southern Africa has contributed to
a significant decrease in HIV/AIDS disease burden [6].
Globally, the number of people accessing ART has almost
tripled from 7.5 million people in 2010 to 20.9 million in
2017 (61% of whom live in East and Southern Africa) [7].
Young people, on the other hand, are highly vulnerable
to new HIV infections. In particular, Anderson et al. [8]
and Hayes R et al. [9] highlighted that over half of all
new HIV infections worldwide currently occur among
young people. In Southern Africa, adolescent girls and
young women aged 15–24 contribute to an estimated
74% of all new infections and have up to eight times
more infections than their male counterparts [6, 10]. An
estimated 2000 new HIV infections are reported to
occur among young women and girls every week in
South Africa [11]. These high HIV incidence rates in
young women have been shown to be largely driven by
age-disparate and transactional sexual relationships be-
tween young women and older men who recently
acquired HIV [12, 13].
Notably “key populations” in turn bears a disproportion-
ate risk of HIV infection compared to the general popula-
tion [14–18], defined as either men who have sex with
men (MSM) or transgender (TG) persons or female sex
workers (FSWs) or injecting drug users (IDUs). United
Nations Programme on HIV/AIDS (UNAIDS) 2018 [1]
estimates just under 50% of global new infections to be
attributed to these populations. However, despite well-
characterized risks for HIV acquisition and transmission,
this group remains a “hard-to-reach” population in part
due to stigmatization and criminalization among other
reasons [19, 20]. For that reason, we will not be including
this population group in our systematic review.
There have been systematic reviews that have focused
on interventions aimed at HIV-positive individuals, such
as initiation of ART [21, 22], support for ART adherence
and retention in care [23–26], linkage to care [27], HIV
care [28, 29], and interventions aimed at preventing new
infections such as abstinence, be faithful, and condomise
(ABC), voluntary male medical circumcision (VMMC),
prevention of mother-to-child HIV transmission (PMTCT)
[30, 31], microbicides, and pre-/post-exposure prophylaxis
(PREP/PEP) [32]. To our knowledge, there is no system-
atic review that has evaluated the effects of ART inter-
vention studies focused on the adult population on the
HIV incidence in young women. In this review, we will
measure the effects of ART use on the incidence of
HIV in young women.
The data from this review will be used to inform a
simulation modeling project, in addition to data from
the Eswatini (formerly known as Swaziland)-based
implementation study on Early Access to ART for All
(EAAA) which evaluated the outcomes associated with
offering early ART to all adults with HIV [33].
Objectives
The objective of this systematic review is to summarize
the effects of ART in HIV-positive adults on new HIV
infection among young women aged 15 to 24 years.
Methods and design
This protocol is written in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis
Protocols (PRISMA-P) checklist (see Additional file 1) [34].
This systematic review protocol has been registered and pub-
lished with the United States National Institute of Health
Research (NIHR) Prospective Register of Systematic Reviews
(PROSPERO) registration number CRD42018099174.
Criteria for considering studies for review
Types of studies
We will include randomized and non-randomized clin-
ical trials and cohort studies.
Type of participants
We will identify studies that include young women aged
15–24 years who are not infected with HIV. The studies
should also include HIV-infected adults who are on anti-
retroviral treatment.
Types of interventions/exposures
Adults aged 18 years or more receiving ART: triple drug
combination ART given as treatment for HIV/AIDS.
Types of outcomes
While the intervention (expanded access to ART) will
occur at the population level, the population of interest is
the young women aged 15–24 years, and therefore out-
comes will only be measured in this target population.
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Primary outcomes
The incidence of HIV infection in young women aged
15–24 years: the proportion of young women with new
infections.
Secondary outcomes
The information collected here will be for young women
aged 15–24 years. This information will help in synthesiz-
ing the information on the conditions necessary to realize
the results reported in the primary outcome.
ART initiation: the proportion of HIV-positive study
participants who started ART.
Retention in care: number of patients who remain
connected to medical care as defined by the study
authors.
ART adherence: the proportion of participants catego-
rized as adherent to ART based on measures reported by
the authors.
Viral load suppression: the proportion of patients with
undetectable viral load following ART initiation or as
defined by the study authors.
Exclusion criteria
We will exclude studies that focus on: pediatric populations
(defined as infancy, between birth, and 2 years; childhood,
2–12 years and early adolescence, 11–14 years) [35], PREP/
PEP interventions, mother-to-child HIV transmission, and
key populations, which are defined here as men who have
sex with men (MSM) or transgender (TG) persons or
female sex workers (FSWs) or injecting drug users (IDUs).
Search methods for identification of the studies
We will conduct a comprehensive and exhaustive search
of published and unpublished literature. We will search
the following electronic databases: MEDLINE (detailed
search strategy is provided in the Additional file 2),
Excerpta Medica Database (EMBASE), Scopus, Google
Scholar, Cochrane Central Register of Controlled Trials
(CENTRAL), WHO’s library database, and Latin Ameri-
can and Caribbean Health Sciences Literature (LILACS).
We will also search conference abstracts from the
conferences such as International AIDS Society (IAS)
Conference, the International Conference on HIV/AIDS
and Sexually Transmitted Infections in Africa (ICASA),
and the Conference on Retroviruses and Opportunistic
Infections (CROI). We will search for gray literature to
identify any relevant unpublished literature, and the
identified literature will be appraised through the
Authority, Accuracy, Coverage, Objectivity, Date, and
Significance (AACODS) checklist [36].
We will also check the reference lists of all included
studies and relevant systematic reviews to identify
additional studies missed from the original electronic
searches.
We will restrict our search to articles published in
English and those published from 1996 (start of the
triple-drug combination ART era).
Selection of studies
The results of the search will be uploaded in Covidence
[37], a web-based online platform which facilitates
screening and selection of articles. The screening will be
carried out in two stages using pre-specified screening
criteria. First, titles and abstract screening will be done
by two reviewers (TC, MK) working independently.
Full-text versions of the relevant studies will then be
downloaded and screened for eligibility by two reviewers
(TC, MK) working independently. We will extract data
from the selected studies onto a pre-tested Microsoft Excel
spreadsheet. If any disagreements occur, these will be re-
solved by discussion and if disagreements persist, it will be
resolved by arbitration from a third reviewer (LM or PN).
Data extraction, management, and analysis
Data from the full-text articles will be extracted by two
independent authors (TC, MK) using a standardized ex-
traction form. Any discrepancy will be resolved by con-
sensus or with referral to a third author if disagreement
persists. The data extraction form to be used to extract
relevant information from the eligible studies has been de-
veloped to include four main heading: bibliometric infor-
mation, participant’s demographics, reported outcomes,
and article research variables. A detailed description of the
extraction form is provided in Additional file 3. Any
changes to be made during the extraction process will be
reported in the final manuscript.
In the event that there is missing information, we need
clarification about study conduct or the studies have
relevant data that is not reported in the published manu-
script, we will contact the authors for additional infor-
mation which may include de-identified individual
patient data.
Risk of bias in randomized studies will be assessed
using the Cochrane “risk of bias” tool [38], and the risk
of bias for cohort studies will be assessed using the risk
of bias in non-randomized studies of interventions
(ROBINS-I) [39].
Though we do not anticipate to having sufficient data to
perform a meta-analysis, we state here the possibility that if
the identified studies are relatively homogeneous in terms of
methodology and outcomes, meta-analyses of the data will
be performed. Funnel-plots and Egger’s test will be used to
determine publication bias. Sufficiently similar data will be
pooled using the inverse variance approach to accommodate
crude and adjusted odds ratios where possible. Given the
purpose of this review, i.e., to collect data to inform a simula-
tion model, no subgroup analyses are planned.
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Statistical heterogeneity will be quantified using the I2
statistic, with an I2 statistic of 75–100 considered high
[40]. A random effects model will be used, and we will
report prediction intervals (PI) as opposed to CIs for
better appreciation of uncertainty around effect estimate
[41]. If clinical heterogeneity precludes a meta-analysis,
a narrative synthesis will be performed. All analysis will
be performed using R software [42].
The quality of evidence will be assessed using the
Grading of Recommendations Assessment Development
and Evaluation (GRADE) approach [43]. An overall
GRADE certainty of evidence (high, moderate, low, very
low) will be based on an appraisal of the body of evi-
dence for items such as the risk of bias, imprecision, in-
directness, and publication bias. Any disagreements will
be recorded and resolved by consensus.
Discussion
Preventing new HIV infection is a critical component of
the global response to the epidemic [44]. The body of
evidence supporting the efficacy of TasP is expanding
quickly. However, most of the studies are still focused
on the adult population [45] with limited data on
outcomes in young women.
To bridge this gap of evidence, the estimates from this
review will inform an individual-based heterosexual HIV
transmission simulation modeling, which will also in-
clude data from an Eswatini-based implementation study
on Early Access to ART for All (EAAA) [33]. The EAAA
study aims to evaluate the feasibility, acceptability, clin-
ical outcomes, affordability, and scalability of offering
early ART to all adults with HIV aged 18 years or more
in the government-managed health system.
The EAAA study will provide clinical, biological, and
behavioral data to ensure that the model mimics the
real-world HIV transmission and incidence among
young women.
Evidence from this systematic review will provide
valuable insights to the modeling arm of the project by syn-
thesizing evidence from studies that measure the effects of
ART among HIV-positive adults on HIV infection among
young women in diverse settings.
This protocol has some limitations. It may be challen-
ging to find studies with data on women aged less than
18 years because the legal age of consent is 18 years in
most countries. Due to limited translation resources, we
are only able to review articles published in English—
this could result in articles that are published in other
languages being excluded.
The strengths of this project lie in its novelty. This is
the first systematic review to look at the impact of ART
use among adults on HIV infection in young women.
Our robust search strategy will ensure a comprehensive
body of evidence.
We anticipate that the review will provide valuable in-
formation to inform the WHO 90-90-90 targets (diagnose
90% of all HIV-positive individuals and provide antiretro-
viral treatment to 90% of those diagnosed with HIV and
for those on treatment, 90% will achieve viral suppression
by 2020) [46]. We speculate that our model, which models
the effect of providing ART to 90% of the people with
HIV, will show a reduction in new HIV infection among
young women in support of and reinforcing the need to
adopt the TasP strategy to curb new HIV infections among
young women. Any changes made to the protocol will be
reported in the final manuscript.
Ethics and dissemination
The study does not require ethical approval because we
will use already published data extracted from manu-
scripts. The results of this systematic review will be
disseminated in peer-reviewed journals and conference
presentations.
Additional files
Additional file 1: PRISMA-P 2015 checklist. (DOCX 30 kb)
Additional file 2: Draft search strategy—MEDLINE (PubMed).
(DOCX 15 kb)
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